Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2 Small Cell Lung Carcinoma 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Neoplasms by Histologic Type 1 Neoplasms 1 Myeloproliferative Disorders 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid 1 Leukemia 1 Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1 Hematologic Diseases 1 Endometrial Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Bone Marrow Diseases 1 Abiraterone Acetate 1

Interventions

Paclitaxel 25 Doxorubicin 15 Carboplatin 14 pembrolizumab 10 Cisplatin 8 Radiotherapy 6 Docetaxel 5 Chemotherapy, Adjuvant 5 Taxes 4 Filgrastim 4 Brachytherapy 4 lenvatinib 3 Observation 3 trastuzumab deruxtecan 2 selinexor 2 olaparib 2 durvalumab 2 Tamoxifen 2 Specimen Handling 2 Ifosfamide 2 Drug Therapy 2 sintilimab 1 sacituzumab govitecan 1 pertuzumab 1 nanocis 1 liposomal doxorubicin 1 ixabepilone 1 gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1 dostarlimab 1 atezolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Endometrial Neoplasms × BID protein, human × Clear all

NCT06712472 2026-01-20

RAINBO-RED

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting

Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡